Osteotech Grafton Flex bone matrix launch planned for fourth quarter.
This article was originally published in The Gray Sheet
Executive SummaryOSTEOTECH GRAFTON FLEX BONE MATRIX INTRODUCTION SLATED FOR FOURTH QUARTER of this year, company President and CEO Richard Bauer said Sept. 20 at the Bear Stearns health care conference in New York City. Describing the advantages of the flexible version of Grafton over the current product, Bauer explained that it "conforms to the natural anatomy. You can customize it, you can cut it, you can suture it."
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.